Characterization of the Binding of [3H]-clobenpropit to Histamine H3-receptors in Guinea-pig Cerebral Cortex Membranes
Overview
Authors
Affiliations
1 We have investigated the binding of a novel histamine H3-receptor antagonist radioligand, [3H]- clobenpropit ([3H]-VUF9153), to guinea-pig cerebral cortex membranes. 2 Saturation isotherms for [3H]-clobenpropit appeared biphasic. Scatchard plots were curvilinear and Hill plot slopes were significantly less than unity (0.63+/-0.03; n = 12+/-s.e.mean). The radioligand appeared to label two sites in guinea-pig cerebral cortex membranes with apparent affinities (pKD') of 10.91+/-0.12 (Bmax = 5.34+/-0.85 fmol mg(-1) original wet weight) and 9.17+/-0.16 (Bmax = 23.20+/-6.70 fmol mg(-1)). 3 In the presence of metyrapone (3 mM) or sodium chloride (100 mM), [3H]-clobenpropit appeared to label a homogeneous receptor population (Bmax=3.41+/-0.46 fmol mg-1 and 3.49+/-0.44 fmol mg(-1), pKD' = 10.59+/-0.17 and 10.77+/-0.02, respectively). Scatchard plots were linear and Hill slopes were not significantly different from unity (0.91+/-0.04 and 0.99+/-0.02, respectively). Granisetron (1 microM), rilmenidine (3 microM), idazoxan (0.3 microM), pentazocine (3 microM) and 1,3-di-(2-tolyl)guanidine (0.3 microM) had no effect on the binding of [3H]-clobenpropit. 4 The specific binding of [3H]-clobenpropit appeared to reach equilibrium after 25 min at 21+/-3 degrees C and remained constant for >180 min. The estimated pKD' (10.27+/-0.27; n = 3+/-s.e.mean) was not significantly different from that estimated by saturation analysis in the presence of metyrapone. 5 A series of histamine H3-receptor ligands expressed affinity values for sites labelled with [3H]-clobenpropit which were not significantly different from those estimated when [3H]-R-alpha-MH was used to label histamine H3-receptors in guinea-pig cerebral cortex membranes.
Morales-Figueroa G, Marquez-Gomez R, Gonzalez-Pantoja R, Escamilla-Sanchez J, Arias-Montano J ACS Chem Neurosci. 2014; 5(8):637-45.
PMID: 24884070 PMC: 4140591. DOI: 10.1021/cn500001m.
HARPER E, Black J Br J Pharmacol. 2007; 151(4):504-17.
PMID: 17401438 PMC: 2013973. DOI: 10.1038/sj.bjp.0707243.
HARPER E, Shankley N, Black J Br J Pharmacol. 2007; 151(1):128-43.
PMID: 17351664 PMC: 2012978. DOI: 10.1038/sj.bjp.0707174.
Witte D, Yao B, Miller T, Carr T, Cassar S, Sharma R Br J Pharmacol. 2006; 148(5):657-70.
PMID: 16715122 PMC: 1751875. DOI: 10.1038/sj.bjp.0706752.
Floran B, Garcia M, Aceves J, Young J Br J Pharmacol. 2001; 133(1):165-71.
PMID: 11325806 PMC: 1572768. DOI: 10.1038/sj.bjp.0704053.